Equashield is a leading global provider of closed system transfer devices (CSTDs) designed to protect healthcare professionals from exposure to hazardous drugs.
With a relentless focus on quality, safety, and ease of use, Equashield’s product offerings are based on proprietary technologies spanning both manual CSTDs and novel automated compounding solutions – including a next-generation automated compounding system utilising artificial intelligence to deliver superior performance.
Company Background
- Since its founding in 2009, Equashield has recorded robust growth fuelled by continued product innovation, high customer satisfaction, and the pioneering of new technological solutions for handling hazardous drugs.
- Products are sold across five continents Equashield is a leading CSTD provider in the largest global market, the US.
Vision & Outlook
- Opportunity to leverage its technological edge to further accelerate growth.
- Pipeline of innovative compounding technologies, including a novel automated drug compounding system.
- Vast potential of compounding automation to improve safety and efficiency in the handling of hazardous drugs.
![EQ Logo CMYK 2021 2](/media/4seme3al/eq-logo-cmyk_2021-2.jpg?mode=max&quality=90&rnd=133153165206230000)
SECTOR
Healthcare
REVENUES 2023
EUR 110 million
EMPLOYEES
450
OWNERSHIP
Fund XI
INVESTMENT DATE
2022
HEAD OFFICE
Tefen, Israel